Diligence memo · auto-generated · as of July 2, 2026
BrightHorse Equine Performance, Inc.
BrightHorse Equine Performance, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
BrightHorse Equine Performance, Inc. operates in Biotechnology, based in SAN MARCOS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BrightHorse Equine Performance, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2023-09-11.
Most recent recorded round closed around 2023-09-11.
Valuation (modeled)modeled
Provath models BrightHorse Equine Performance, Inc. at approximately $1.5M (range $107K–$6.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.47× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 4% of Biotechnology peers (4293 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.